Back to search results

T-Lymphocytes for Adenovirus, CMV, or EBV Infections

This study is testing new ways to fight serious viral infections (Adenovirus, Cytomegalovirus, or Epstein-Barr Virus) in people with weakened immune systems, such as those who have had a transplant. Researchers are evaluating specific types of immune cells called T-lymphocytes (Adenovirus Specific T-Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, or Epstein-Barr Virus Specific T-Lymphocytes). These cells are designed to target and fight off these viruses. The goal is to see if these treatments can effectively reduce the viral infection. The study is open to males and females aged 1 month to 65 years. The study aims to enroll 25 participants, but its current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 25 participants. It is evaluating the effectiveness of specific T-lymphocyte treatments for viral infections.
What's involved
Participants may receive up to 5 cellular infusions from one or two donors, with at least 14 days between infusions. You will be followed for 6 months after your first infusion, and for an additional 90 days from your last infusion for side effects.
Compensation
Not stated in the trial record.
Follow-up
Participants are followed for 6 months after the initial infusion. If additional infusions are given, side effects are monitored for an additional 90 days from the last infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06909110

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Recruiting
PHASE1Ages 1–65InterventionalTreatment
Jessie L. Alexander
~25 participants
Updated 2025-08-14 on ClinicalTrials.gov
What's tested:Adenovirus Specific T- LymphocytesCytomegalovirus Specific T-LymphocytesEpstein-Barr Virus Specific T-Lymphocytes

At a glance

Recruiting sites
2 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Grade III-IV Acute Graft versus host disease
Measured over Day 0 through 90 days after last cellular infusion
+1 more outcome measured

Conditions

Adenovirus
Cytomegalovirus Infections
Epstein-Barr Virus Infections

Explore related trials

Adenovirus InfectionCytomegaloviral InfectionEBV InfectionHematopoietic Cell TransplantationInborn Error of ImmunitySolid organ transplant to recipient

Where it's being run

3 sites across 1 states
California3

Study leadership

  • Jessie Alexander, MD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Jessie L Alexander, MD
[email protected]
6507259250
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Related to the recipient
Apheresis does not need a blood prime before the procedure
Adequate peripheral venous access
Explicit evaluation of the donors' willingness to donate cells, as attested by the research team
Must have understanding that they are helping their ill relative, as attested by the research team
Will gain emotional/psychological benefit from their ability to help and want to donate for a relative, as attested by the research team

What this trial measures

  • Grade III-IV Acute Graft versus host diseaseDay 0 through 90 days after last cellular infusion

    The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.

  • CTCAE Grade 4/5 Adverse EventsDay 0 through 30 days from last cellular infusion

    The incidence of patients who develop CTCAE Grade 4/5 Adverse events related to infusion